Results 71 to 80 of about 1,252,407 (298)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

The CD47-SIRPα Immune Checkpoint

Immunity, 2020
The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted through inhibitory and activating receptors. The Cluster of Differentiation 47 (CD47) protein, expressed on both healthy and cancer cells, plays a pivotal role in this balance by delivering a "don't eat me signal" upon binding to the Signal-regulatory ...
Meike E.W. Logtenberg, Ferenc A. Scheeren, Ton N. Schumacher   +2 more
openaire   +3 more sources

TIGIT as an emerging immune checkpoint [PDF]

Clinical and Experimental Immunology, 2019
Summary T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to down-regulate T cell and natural killer (NK ...
H Harjunpää, C Guillerey
openaire   +5 more sources

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies

Cancer Cell International
Hematological malignancies are typically treated with chemotherapy and radiotherapy as the first-line conventional therapies. However, non-coding RNAs (ncRNAs) are a rapidly expanding field of study in cancer biology that influences the growth ...
Samira Anvari, Mohsen Nikbakht, Mohammad Vaezi, Sedigheh Amini-Kafiabad, Mohammad Ahmadvand   +4 more
doaj   +1 more source

Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer

The International Journal of Biological Markers, 2023
Background Epithelial ovarian cancer (EOC) is the leading cause of death associated with gynecologic tumors. EOC is asymptomatic in early stages, so most patients are not diagnosed until late stages, highlighting the need to develop new diagnostic ...
Azza Habel, Xu Weili, Mariem Hadj Ahmed, Mouna Stayoussef, Hanen Bouaziz, Mouna Ayadi, Amel Mezlini, Anis Larbi, Basma Yaacoubi-Loueslati   +8 more
doaj   +1 more source

Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion

Frontiers in Immunology, 2021
Virulent porcine reproductive and respiratory syndrome virus (PRRSV) strains, such as the Lena strain, have demonstrated a higher thymus tropism than low virulent strains.
Inés Ruedas-Torres, Irene M. Rodríguez-Gómez, José María Sánchez-Carvajal, Silvia Guil-Luna, Fernanda Larenas-Muñoz, Francisco J. Pallarés, Librado Carrasco, Jaime Gómez-Laguna   +7 more
doaj   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

Cell Communication and Signaling, 2023
Acute myeloid leukemia (AML) comprises a multifarious and heterogeneous array of illnesses characterized by the anomalous proliferation of myeloid cells in the bone marrow microenvironment (BMM). The BMM plays a pivotal role in promoting AML progression,
Maryam Bakhtiyari, Mahsa Liaghat, Fatemeh Aziziyan, Hooriyeh Shapourian, Sheida Yahyazadeh, Maedeh Alipour, Shaghayegh Shahveh, Fahimeh Maleki-Sheikhabadi, Hossein Halimi, Razieh Forghaniesfidvajani, Hamidreza Zalpoor, Mohsen Nabi-Afjadi, Majid Pornour   +12 more
doaj   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells

Frontiers in Immunology, 2018
Among the most promising therapeutic modalities for cancer treatment is the blockade of immune checkpoint pathways, which are frequently co-opted by tumors as a major mechanism of immune escape.
Nayoung Kim, Nayoung Kim, Hun Sik Kim, Hun Sik Kim, Hun Sik Kim   +4 more
doaj   +1 more source